Nightingale Health

0.86 EUR

-0.23 %

4,704 following

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-0.23 %
-24.07 %
-44.43 %
-58.15 %
-61.35 %
-70.05 %
-13.51 %
-83.47 %
-83.34 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more
Market cap
52.29M EUR
Turnover
192.29K EUR
P/E (adj.) (26e)
-3.24
EV/EBIT (adj.) (26e)
-0.72
P/B (26e)
0.99
EV/S (26e)
1.49
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
1.70 EUR
Updated
2026-03-05
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 2026-03-06

Latest extensive report

Released: 2025-06-13

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16/9
2026

Annual report '26

5/11
2026

General meeting '26

9/3
2027

Interim report Q2'27

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
The essential part (and news to me) is that the goal with ELOISA is to pilot and build a model that can be scaled to other welfare areas. This means there’s no need to pilot every area from scratch.
yesterday
by Puutaheinää
12
Without getting bogged down in individual cents, we are currently very close to ATL (all-time low) levels. I decided to jump on board now, as it feels like the heavy sell-off (vomiting of shares) won’t last much longer, and I consider Cor Group’s (Olli Karhi) recent share purchase...
5/27/2026, 9:26 AM
by Axelrod
8
Here are Antti’s comments regarding the company’s latest announcement. Nightingale Health announced on Thursday that it is participating in a research and development project launched by the South Savo Welfare District Eloisa, where the company’s blood analysis technology is combined...
18 hours ago
by Sijoittaja-alokas
7
Now the news is starting to come in… Nightingale Health involved in South Savo Welfare District Eloisa’s proactive healthcare research project - Inderes
yesterday
by Tuuukka
7
Below are the findings and the significance for medicine and drug development from the recent study “Genetic analysis of circulating metabolic traits in 619,372 individuals,” presented in a more accessible format using Google’s NotebookLM: drive.google.com Decoding_Human_Genetics...
yesterday
by The Ugly Buckling
6
I just re-read the CEO’s words from the latest interim report for a refresher, and despite the share price drop, they make me want to hold onto my shares even tighter. Sales ramp-ups on all fronts, pilots starting, etc. Unless those words are just hot air, these efforts will surely...
yesterday
by Puutaheinää
6
Here is something to ponder, in case anyone has any thoughts on the matter, as this is what puzzles me the most right now: why did the sale of the Kirin/Mitsui stake to COR Group at near ATL (all-time low) prices immediately trigger a sell-off by a large nominee-registered holder...
10 hours ago
by Puutaheinää
4
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.